# Are GLP-1s safe long term? What the longest trials show

Source: https://pepvault.app/guides/are-glp-1s-safe-long-term

Last updated: 2026-11-20

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Guides](https://pepvault.app/guides) [GLP-1s](https://pepvault.app/guides#glp1)

# Are GLP-1s safe long term? What the longest trials show

Reviewed November 2026 21 sources [Published by PepVault](https://pepvault.app/guides/how-we-research)

The longest GLP-1 trials ran 2 to 5.4 years, and heart events and deaths were the same or lower on the drug. The long-term risks, the thyroid warning, cycling.

- **Last reviewed:** Nov 20, 2026
- **Sources:** 21
- **Questions:** 7
- **Compounds:** 5

## The short answer

The longest GLP-1 trials followed people for 2 to 5.4 years, and heart attacks, strokes and deaths came out the same or lower on the drug than on placebo or an older GLP-1. The risks the labels warn about are stomach side effects, gallbladder problems, rare pancreatitis and, in diabetes, eye changes. The thyroid tumor warning comes from rodents. No label describes a cycle: they are written for continuous use.

- The longest trials ran two to five years; the longest, REWIND, ran a median 5.4 years.
- In the outcome trials, heart events were lower on the drug or no worse than an older GLP-1.
- Gallbladder problems rise with longer use; thyroid cancer is a rodent finding, unsettled in people.
- The labels describe weekly use with no end date and no off-weeks.

Every number checked at its primary source · Nov 20, 2026 · [21 sources](https://pepvault.app/guides/are-glp-1s-safe-long-term#sources) · [How we research](https://pepvault.app/guides/how-we-research)

**Evidence:** Randomised trials in people lasting two to five years (outcome trials and long weight trials, all sponsored by the drugs' makers), a meta-analysis of 76 trials, three large health-record studies, the four FDA labels, an FDA safety review and a European Medicines Agency review; the thyroid tumor finding is from rodents.

## How long are the longest GLP-1 trials?

The longest data come from **outcome trials**: large studies built to count heart attacks, strokes and deaths, so they keep thousands of people on the drug for years. The table gathers nine of the longest trials of GLP-1 drugs on sale today, each two years or more, with each one's length and what it found on safety, against placebo unless it says otherwise.

| Trial | Drug | Who took part | How long | What it found on safety |
| --- | --- | --- | --- | --- |
| REWIND | Dulaglutide (Trulicity) | 9,901 adults with type 2 diabetes | Median 5.4 years | Heart events 12.0% vs 13.4%; stomach side effects 47.4% vs 34.1%[12](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-12) |
| SOUL | Oral semaglutide (Rybelsus) | 9,650 adults with type 2 diabetes and heart or kidney disease | Median 49.5 months | Heart events 12.0% vs 13.8%; serious adverse events 47.9% vs 50.3%[14](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-14) |
| SURPASS-CVOT | Tirzepatide (Mounjaro) vs dulaglutide | 13,299 adults with type 2 diabetes and heart disease | Median 210 weeks, about 4 years | Heart events 12.2% vs 13.1%, no worse than dulaglutide; more stomach side effects[3](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-3) [11](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-11) |
| LEADER | Liraglutide (Victoza) | 9,340 adults with type 2 diabetes | Median 3.8 years | Heart events 13.0% vs 14.9%; deaths 8.2% vs 9.6%; pancreatitis not higher[6](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-6) |
| SELECT | Semaglutide 2.4 mg (Wegovy) | 17,604 adults with heart disease and overweight, no diabetes | Mean 39.8 months | Heart events 6.5% vs 8.0%; stopped for a side effect 16.6% vs 8.2%[7](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-7) |
| FLOW | Semaglutide 1 mg (Ozempic) | 3,533 adults with type 2 diabetes and kidney disease | Median 3.4 years | Serious adverse events 49.6% vs 53.8%[13](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-13) |
| SURMOUNT-1, 3-year part | Tirzepatide (Zepbound) | 1,032 adults with obesity and prediabetes | 176 weeks, then 17 weeks off | No new safety signals; stomach effects mostly in the first 20 weeks[10](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-10) |
| SUSTAIN-6 | Semaglutide (Ozempic) | 3,297 adults with type 2 diabetes | 104 weeks | Heart events 6.6% vs 8.9%; more diabetic eye complications[5](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-5) |
| STEP 5 | Semaglutide 2.4 mg (Wegovy) | 304 adults with obesity, no diabetes | 104 weeks | Stomach side effects 82.2% vs 53.9%, mostly mild to moderate[9](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-9) |

Two points stand out. First, the drugs passed the test these trials were built for: none raised heart events, and most of the outcome trials lowered them. Second, the controlled record stops at about five years. Anything said about ten or twenty years of use rests on health-record studies, which can show a link but not prove a cause.

<!--promo-->

Long-term use is easier to review with your own record. PepVault logs each weekly dose and any side effect with its date and severity, so months of use sit in one place. [Log it in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-are-glp-1s-safe-long-term-inline&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Long-term use is easier to review with your own record. PepVault logs each weekly dose and any side effect with its date and severity, so months of use sit in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## Did fewer people die on a GLP-1 in the long trials?

In several of them, yes. In LEADER, 8.2% of people on liraglutide died over the trial against 9.6% on placebo, and deaths from heart causes fell from 6.0% to 4.7%[6](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-6). In SELECT, heart attacks, strokes and heart deaths together dropped from 8.0% to 6.5% in people without diabetes, a 20% lower risk[7](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-7). In FLOW, deaths from any cause were 20% lower[13](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-13); in REWIND the gap, 10.8% against 12.0%, was too small to rule out chance[12](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-12). Over four years of SELECT, people on semaglutide also had fewer serious adverse events than those on placebo, in every weight group[8](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-8).

Tirzepatide was tested against another GLP-1 instead of placebo. In SURPASS-CVOT it was no worse than dulaglutide on heart events, and fewer people died on it: 8.5% against 10.1%, a result the Mounjaro label marks as not controlled for multiple testing[3](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-3). Weight loss also held: 10.2% below the starting weight at four years in SELECT[8](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-8), and 12.3% to 19.7% at three years in SURMOUNT-1, depending on the dose[10](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-10).

## What are the long-term side effects of GLP-1s?

The trials found four that matter over years.

- **Stomach side effects.** Nausea, diarrhoea and vomiting are the most common, mostly while the dose is climbing. They are also the main reason people stop: in SELECT, 16.6% stopped for a side effect against 8.2% on placebo[7](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-7).
- **Gallbladder problems.** Gallstones and gallbladder swelling (cholecystitis) are more common. Across 76 trials the risk was 37% higher on a GLP-1; the rise showed up with longer use, not shorter, and was largest in weight-loss trials[15](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-15). In Wegovy's weight trials of the shot, gallstones were reported by 1.6% against 0.7% on placebo[2](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-2).
- **Pancreatitis.** Inflammation of the pancreas is rare, and all four labels warn about it[1](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-1) [2](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-2) [3](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-3) [4](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-4). In LEADER, it was not more common on liraglutide than on placebo[6](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-6).
- **Diabetic eye changes.** In SUSTAIN-6, diabetic eye complications came to 3.0% on semaglutide against 1.8% on placebo, and the rise was larger in people who already had eye disease (8.2% against 5.2%) than in those without (0.7% against 0.4%). The label links it to blood sugar falling fast, which can briefly worsen the eyes[1](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-1).

**Commonly reported:** in the open write-ups of 41 people who took semaglutide that our reports page counted (2019 to 2026), less appetite and weight loss led, and nausea or an upset stomach was the unwanted effect named most, 14 times[20](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-20).

**When to get help** Wegovy's guide for patients says to stop the shot and call your prescriber right away for severe stomach pain that will not go away, sometimes felt through to the back; pain in the upper belly, a fever, or yellow skin or eyes are also reasons to call[2](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-2).

## With this guide

### Semaglutide

- [Semaglutide: the full reference](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)
- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)

### Studies

- [Semaglutide: 11.85% more weight loss than placebo without diabetes](https://pepvault.app/research/semaglutide-tan-2022)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 31 studies](https://pepvault.app/research#semaglutide)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)
- [Liraglutide vs Semaglutide](https://pepvault.app/peptides/compare/liraglutide-vs-semaglutide)
- [Semaglutide vs Dulaglutide](https://pepvault.app/peptides/compare/semaglutide-vs-dulaglutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Maintenance dose](https://pepvault.app/glossary/maintenance-dose)
- [Cycle](https://pepvault.app/glossary/cycle)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Boxed warning](https://pepvault.app/glossary/boxed-warning)

## Do GLP-1s cause thyroid cancer?

Each label opens with a **boxed warning**, the FDA's strongest label warning, on thyroid C-cell tumors. It comes from rodent studies: lifelong doses caused these tumors in mice and rats, at exposures close to what people get. Whether that happens in people is not known, and the labels say so[1](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-1) [2](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-2) [3](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-3) [4](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-4).

| Label | Animals with tumors | In people | Who it rules out |
| --- | --- | --- | --- |
| Ozempic (June 2026) | Mice and rats | Unknown | Personal or family history of medullary thyroid cancer, or MEN 2[1](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-1) |
| Wegovy (June 2026) | Mice and rats | Unknown | The same[2](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-2) |
| Mounjaro (Sept 2026) | Rats, both sexes | Unknown | The same[3](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-3) |
| Zepbound (Sept 2026) | Rats | Unknown | The same[4](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-4) |

Medullary thyroid cancer is a rare cancer of the C-cells, and MEN 2 is an inherited condition that causes it. Wegovy's label adds that cases have been reported in people on liraglutide, with data too thin to show or rule out a cause[2](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-2).

Two large health-record studies point in different directions. A French study of people with diabetes found a higher thyroid cancer risk after 1 to 3 years of GLP-1 use (hazard ratio 1.58)[16](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-16). A study across Denmark, Norway and Sweden of 145,410 people on a GLP-1, followed for a mean 3.9 years, found no rise (hazard ratio 0.93), compared with another diabetes drug[17](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-17). The labels list the signs to report: a lump or swelling in the neck, hoarseness, trouble swallowing or shortness of breath[2](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-2).

The tumor finding is from mice and rats. The labels say its relevance to people has not been determined, and that routine blood calcitonin tests or neck ultrasounds are of uncertain value for catching this cancer early[2](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-2).

## What changed in the GLP-1 labels in 2025 and 2026?

Three changes matter for long-term use. In January 2026, the FDA asked for the warning on suicidal behaviour and thoughts to come off the weight-loss labels: its review of 91 placebo-controlled trials in about 107,910 people found no raised risk[21](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-21). Wegovy's and Zepbound's lists of recent changes mark it as removed in February 2026[2](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-2) [4](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-4). In August 2026, Mounjaro's label added a use on the SURPASS-CVOT results: lowering the risk of heart attacks, strokes and heart deaths in adults with type 2 diabetes at high risk of them[3](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-3).

In June 2025, the European Medicines Agency's safety committee concluded that NAION, a sudden loss of blood flow to the optic nerve that can affect sight, is a very rare side effect of semaglutide: up to 1 in 10,000 people, or about one extra case per 10,000 person-years of use[19](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-19). The current US Ozempic and Wegovy labels do not list it[1](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-1) [2](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-2).

## Do you need to cycle a GLP-1?

No label describes a cycle. A **cycle** means set weeks on a compound and then off, a habit borrowed from other peptides. Wegovy and Zepbound are approved to reduce weight and to "maintain weight reduction long term," with a weekly maintenance dose and no end date[2](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-2) [4](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-4). Ozempic and Mounjaro are diabetes drugs taken weekly for as long as they are prescribed[1](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-1) [3](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-3). None of the trials above tested on-and-off use.

Breaks have a cost the labels spell out. Semaglutide stays in the blood for about 5 weeks after the last dose[1](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-1), and after two or more missed weekly doses, Wegovy's label restarts the dose climb at a lower dose to limit stomach side effects[2](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-2). In the trials that stopped the drug, most of the lost weight came back within a year; our guide on stopping a GLP-1 has those numbers.

<!--promo-->

PepVault sends a reminder on your dose day, so a weekly shot is not missed by accident. [Set reminders in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-are-glp-1s-safe-long-term-inline&mt=8)

<!--/promo-->

## What is still unknown about long-term GLP-1 use?

Three things. The trials stop at about five years, so decades of use rest on health records. The rodent thyroid finding has not been settled in people. And the largest health-record map so far, of 215,970 US veterans with diabetes who started a GLP-1, found links in both directions: fewer cases of dementia, seizures, addiction and heart and metabolic disease, and more stomach problems, low blood pressure, fainting, arthritis, kidney stones and drug-related pancreatitis[18](https://pepvault.app/guides/are-glp-1s-safe-long-term#source-18). Those are associations, not proven effects.

Whether to stay on a GLP-1, and for how long, is a decision for you and your prescriber, who knows your history.

<!--promo-->

PepVault's doctor's report puts your doses, consistency, weight and logged side effects on one page to bring to that appointment. [Track your weight in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-are-glp-1s-safe-long-term-inline&mt=8)

<!--/promo-->

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-next&mt=8)

<!--/promo-->

## Sources

1. OZEMPIC (semaglutide) injection, prescribing information. Novo Nordisk. DailyMed, version 20, updated June 1, 2026 (published June 10, 2026). [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79)
2. WEGOVY (semaglutide) injection and tablets, prescribing information and Medication Guide. Novo Nordisk. DailyMed, version 19, updated June 18, 2026 (published June 30, 2026). [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b)
3. MOUNJARO (tirzepatide) injection, prescribing information. Eli Lilly. DailyMed, version 40, updated August 27, 2026 (published September 2, 2026). [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0)
4. ZEPBOUND (tirzepatide) injection, prescribing information. Eli Lilly. DailyMed, version 40, updated August 28, 2026 (published September 2, 2026). [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b)
5. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016. [PubMed 27633186](https://pubmed.ncbi.nlm.nih.gov/27633186/)
6. Marso SP et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med. 2016. [PubMed 27295427](https://pubmed.ncbi.nlm.nih.gov/27295427/)
7. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023. [PubMed 37952131](https://pubmed.ncbi.nlm.nih.gov/37952131/)
8. Ryan DH et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024. [PubMed 38740993](https://pubmed.ncbi.nlm.nih.gov/38740993/)
9. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022. [PubMed 36216945](https://pubmed.ncbi.nlm.nih.gov/36216945/)
10. Jastreboff AM et al. Tirzepatide for obesity treatment and diabetes prevention (SURMOUNT-1, 3 years). N Engl J Med. 2025. [PubMed 39536238](https://pubmed.ncbi.nlm.nih.gov/39536238/)
11. Nicholls SJ et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes (SURPASS-CVOT). N Engl J Med. 2025. [PubMed 41406444](https://pubmed.ncbi.nlm.nih.gov/41406444/)
12. Gerstein HC et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). Lancet. 2019. [PubMed 31189511](https://pubmed.ncbi.nlm.nih.gov/31189511/)
13. Perkovic V et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med. 2024. [PubMed 38785209](https://pubmed.ncbi.nlm.nih.gov/38785209/)
14. McGuire DK et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes (SOUL). N Engl J Med. 2025. [PubMed 40162642](https://pubmed.ncbi.nlm.nih.gov/40162642/)
15. He L et al. Association of GLP-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2022. [PubMed 35344001](https://pubmed.ncbi.nlm.nih.gov/35344001/)
16. Bezin J et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023. [PubMed 36356111](https://pubmed.ncbi.nlm.nih.gov/36356111/)
17. Pasternak B et al. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ. 2024. [PubMed 38683947](https://pubmed.ncbi.nlm.nih.gov/38683947/)
18. Xie Y et al. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat Med. 2025. [PubMed 39833406](https://pubmed.ncbi.nlm.nih.gov/39833406/)
19. European Medicines Agency. PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy. June 6, 2025 (revised June 13, 2025). [ema.europa.eu](https://www.ema.europa.eu/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy)
20. PepVault. Semaglutide: what people report (41 people's open write-ups, 2019 to 2026, counted November 19, 2026). [pepvault.app](https://pepvault.app/peptides/semaglutide/reviews)
21. US Food and Drug Administration. FDA requests removal of suicidal behavior and ideation warning from glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. Drug Safety Communication, January 13, 2026. [fda.gov](https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp)

<!--promo-->

Newsletter · Weekly

## The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

<!--/promo-->

## Next guide · GLP-1

Guide · GLP-1

### [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)

Ozempic is approved to slow kidney disease after the FLOW trial, yet every GLP-1 label warns of kidney injury from dehydration. Both sides, label by label.

Read the next guide

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## In the library

- [Semaglutide Studied range: 0.25–2.4 mg](https://pepvault.app/peptides/semaglutide)
- [Tirzepatide Studied range: 2.5–15 mg](https://pepvault.app/peptides/tirzepatide)
- [Liraglutide Studied range: 0.6–3 mg](https://pepvault.app/peptides/liraglutide)
- [Dulaglutide Studied range: 0.75–4.5 mg](https://pepvault.app/peptides/dulaglutide)
- [Semaglutide (oral) Studied range: 1.5–25 mg](https://pepvault.app/peptides/semaglutide-oral)

## Related guides

- Guide · GLP-1s

  ### [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)

  What happened to weight when semaglutide and tirzepatide were stopped in STEP 1, STEP 4 and SURMOUNT-4: how much came back, how fast, and what the labels say.

  Read the guide
- Guide · GLP-1s

  ### [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)

  Is retatrutide safe? What its trials counted of pancreatitis, gallbladder and heart events, low blood sugar and deaths, who was left out, and what is unknown.

  Read the guide
- Guide · GLP-1s

  ### [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)

  Ozempic and Wegovy side effects from the labels' trials, drug against placebo: nausea and the rest, when they start, how many days they last, and what helps.

  Read the guide
- Guide · GLP-1s

  ### [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)

  Mounjaro and Zepbound side effects at 5, 10 and 15 mg against placebo, from the labels' trial tables: when they show up, how many stopped, and what helps.

  Read the guide
- Guide · GLP-1s

  ### [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)

  What each trial tested for keeping weight off after a GLP-1: staying on, a lower dose, switching to a pill and exercise, with every result in one by-drug table.

  Read the guide

## Guides

- [All guides](https://pepvault.app/guides)
- [How we research](https://pepvault.app/guides/how-we-research)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this guide

### Semaglutide

- [Semaglutide: the full reference](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)
- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)

### Studies

- [Semaglutide: 11.85% more weight loss than placebo without diabetes](https://pepvault.app/research/semaglutide-tan-2022)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 31 studies](https://pepvault.app/research#semaglutide)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)
- [Liraglutide vs Semaglutide](https://pepvault.app/peptides/compare/liraglutide-vs-semaglutide)
- [Semaglutide vs Dulaglutide](https://pepvault.app/peptides/compare/semaglutide-vs-dulaglutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Maintenance dose](https://pepvault.app/glossary/maintenance-dose)
- [Cycle](https://pepvault.app/glossary/cycle)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Boxed warning](https://pepvault.app/glossary/boxed-warning)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
